Equid herpesvirus 1 (EHV-1) causes respiratory disease, abortion and neurological disorders in horses. Cells from the myeloid lineage (CD172a In contrast, we found that treatment of cells with neuraminidase (NA) reduced infection by 85-100 % compared with untreated cells, whilst NA treatment of virus had no effect on infection. This shows that sialic acid residues present on CD172a + cells are essential in the initiation of EHV-1 infection. We found that a V b 3 integrins are involved in the post-binding stage of CD172a + cell infection. Using pharmacological inhibitors, we showed that EHV-1 does not enter CD172a + cells via a clathrin-or caveolae-dependent endocytic pathway, nor by macropinocytosis, but requires cholesterol, tyrosine kinase, actin, dynamin and endosomal acidification, pointing towards a phagocytic mechanism. Overall, these results show that the narrow tropism of EHV-1 amongst CD172a + cells is determined by the presence of specific cellular receptors.
INTRODUCTION
The entry of enveloped animal viruses into their host cells is mediated either by direct fusion of the viral envelope with the plasma membrane or by endocytosis, which can be pH-independent or -dependent (Marsh & Helenius, 2006) . The entry of the prototype alphaherpesvirus, herpesvirus simplex virus type 1 [HSV-1; human herpesvirus 1 (HHV-1)], into permissive cells can be mediated by both mechanisms and has been shown to be cell-type-dependent (Nicola et al., 2003 (Nicola et al., , 2005 Wittels & Spear, 1991) .
Equid herpesvirus 1 (EHV-1), a member of the subfamily Alphaherpesvirinae, is a major pathogen of horses worldwide. EHV-1 is one of the main causes of respiratory disease, abortion and encephalomyelopathy (Allen & Bryans, 1986; Patel & Heldens, 2005) . Like HSV-1, EHV-1 can enter cells, including rabbit kidney epithelial cells and equine dermal cells, via direct fusion with the plasma membrane (Frampton et al., 2007) . The initial binding of EHV-1 to target cells is mediated via an interaction between virus glycoproteins gB and/or gC and cellular heparan sulphate (Neubauer et al., 1997; Osterrieder, 1999) . The interaction of glycoprotein gD with a putative receptor [MHC class I (MHC-I)] followed by the activation of a gH/gL complex, in combination with gB and gD, are required to complete the fusion between the viral envelope and the cell membrane (Atanasiu et al., 2007; Kurtz et al., 2010; Sasaki et al., 2011) . van de Walle et al. (2008) demonstrated that EHV-1 enters via the endocytic/phagocytic pathway into CHO-K1 cells and PBMCs, and that a V integrins are involved. In addition, Hasebe et al. (2009) indicated that EHV-1 entry pathways are cell-type-dependent.
CD172a
+ monocytic cells were identified as one of the main target cells of EHV-1 in the upper respiratory tract and the bloodstream during primary infection (van der Meulen et al., 2000; Gryspeerdt et al., 2012) . EHV-1 replication was IP: 54.70.40.11
On: Wed, 02 Jan 2019 23:39:31 found to be restricted and delayed in CD172a + cells at a very early stage of infection (Laval et al., 2015a) . It was proposed that CD172a
+ cells may serve as a 'Trojan horse' to facilitate the spread of EHV-1 to target organs and evade immune surveillance. However, at present, little is known about the regulation of CD172a + cell tropism. Here, we investigated the binding and entry of EHV-1 into CD172a + cells. Using 3,39-dioctadecyloxacarbocyanine perchlorate (Dio)-labelled virus particles, we compared the kinetics of EHV-1 binding to CD172a
+ cells and to RK-13 cells, a cell line known to be fully susceptible to EHV-1 infection. Using pharmacological inhibitors and confocal microscopy, we investigated the entry mechanism(s) of EHV-1 into CD172a + cells.
RESULTS

EHV-1 does not bind efficiently to CD172a 1 cells compared with RK-13 cells
To characterize the attachment of EHV-1 to target CD172a + cells, we compared the binding kinetics of Dio-labelled EHV-1 particles to CD172a + cells and RK-13 cells. EHV-1 particles were observed on the plasma membrane of *70 % of RK-13 cells at m.o.i. 1 at 60 min post-binding and this percentage was independent of the EHV-1 (03P37 or 97P70) strains used. At m.o.i. 10, 100 % of RK-13 cells showed virus particles bound on their surface (Fig. 1a) . In contrast, EHV-1 97P70 particles were observed on the plasma membrane of 14 % of CD172a + cells at m.o.i. 1 and this percentage was not significantly higher in cells incubated with EHV-1 03P37 particles (23 %) or with a higher m.o.i. (10) (Fig. 1c) . The number of EHV-1 particles attached to RK-13 cells significantly increased from 15 to 60 min (Pv0.001) (Figs 1 and 2a) . NS NS 0 0 3 P 3 7 9 7 P 7 0 0 3 P 3 7 9 7 P 7 0 0 3 P 3 7 9 7 P 7 0 0 3 P 3 7 9 7 P 7 0 We first performed infection-blocking experiments using a function-blocking antibody against a V b 3 integrin. Blocking antibodies against a 4 b 1 and a L b 2 integrins, which are found expressed on 10-14 and 94 % of CD172a + cells, respectively (Laval et al., 2015b) , were also included in this study to rule out their involvement in EHV-1 infection. Pre-treatment of EHV-1-inoculated CD172a
+ cells with anti-a V b 3 integrin (CD51/61) antibody resulted in a dose-dependent significant decrease of EHV-1 infection in CD172a + cells compared with the isotype control (Pv0.01). When used at a concentration of 50 mg ml 21 , we found that the anti-a V b 3 integrin antibody inhibited EHV-1 infection levels by 70 and 80 % in CD172a
+ cells inoculated with EHV-1 03P37 and 97P70 strains, respectively (Pv0.001) (Fig. 3a) . In contrast, no significant decrease of EHV-1 infection was observed in CD172a a L b 2 (CD11a/CD18)-blocking antibodies at a concentration of either 10 or 50 mg ml 21 (Fig. 3b, c) .
To determine whether the interaction of EHV-1 with a V b 3 integrin occurred during binding or at a post-binding step, we carried out EHV-1 binding-blocking experiments with the blocking antibody directed against a V b 3 integrin. After pre-incubation with 10 mg ml 21 of the antibody against a V b 3 (CD51/61) integrin or an isotype control, CD172a
+ cells were inoculated with Dio-labelled EHV-1 (03P37 or 97P70) particles for 1 h on ice. The percentage of cells with bound virus particles was analysed as described earlier. As shown in Fig. S1 (available in the online Supplementary Material), no significant decrease of EHV-1 03P37 or 97P70 binding to CD172a
+ cells was observed after pre-incubation of cells with a V b 3 antibody compared with the control. Taken together, these results suggested that a V b 3 integrin was not used by EHV-1 for its initial attachment to the CD172a + cell surface, but was rather involved at a post-binding step.
Sialic acids, but not cellular heparan sulphate, play a role in EHV-1 infection of CD172a 1 cells
Heparan sulphate moieties are known to play a role in the binding step of several herpesviruses, including HSV-1, pseudorabies virus and cytomegalovirus (HHV-5) (Compton et al., 1993; Shieh et al., 1992; Shukla & Spear, 2001; Trybala et al., 1998) . However, the role of heparan sulphate in EHV-1 entry into target CD172a + cells as an attachment receptor has not yet been confirmed. To determine whether the interaction of EHV-1 with CD172a + cells also involves heparan sulphate molecules, cells were pre-treated with heparinase I and III blend (heparinase) at 1 or 10 U ml 21 prior to inoculation with EHV-1 (03P37 or 97P70). As a positive control, RK-13 cells were pre-treated with heparinase at 1 U ml 21 before EHV-1 inoculation. As shown in Fig. 4(a) , a significant reduction of EHV-1 infection was observed in heparinase-treated RK-13 cells compared with non-treated cells (Pv0.05). In contrast, we found that enzymic removal of cell surface heparan sulphate did not significantly reduce EHV-1 infection in CD172a
+ cells compared with nontreated cells (Fig. 4b) . This suggested that heparan sulphate did not play a role in EHV-1 entry into CD172a + cells.
To further investigate the nature of the cellular receptor involved in the restricted attachment of EHV-1 to CD172a + cells, we examined the role of sialic acids in EHV-1 infection of CD172a + cells. Sialic acids constitute another group of carbohydrates other than glycosaminoglycans and are known to serve as receptors for several viruses, such as influenza virus, respiratory syncytial virus or polyomaviruses (Barretto et al., 2003; Cahan et al., 1983; Gamblin et al., 2004) . Attachment to sialic acids present on cells is usually mediated by receptor-binding proteins that are constituents of viral envelopes, such as the haemagglutinin (HA) protein for influenza virus (Skehel & Wiley, 2000) . In addition, sialic acid-binding immunoglobulin-like lectins (siglecs) that are expressed on immune cells can recognize sialic acid moieties on the virus, as shown for human immunodeficiency virus type 1 (HIV-1) and porcine reproductive and respiratory syndrome virus infections (Delputte & Nauwynck, 2004; Zou et al., 2011) .
To assess the role of sialic acids in EHV-1 infection on CD172a
+ cells, cells were pre-treated with neuraminidase (NA) at 50 mU ml 21 prior to inoculation with EHV-1. We found that EHV-1 infection was reduced by 100 and 85 % in NA-treated CD172a
+ cells inoculated with EHV-1 03P37 and 97P70, respectively, compared with untreated cells (Pv0.001) (Fig. 4c) . As the presence of sialic acids on the virion surface has been shown to be important in HSV-1 infection (Teuton & Brandt, 2007) , we examined whether sialic acids on EHV-1 were involved in infection of CD172a
+ cells by enzymic removal of sialic acids from the surface of EHV-1. As shown in Fig. 4 
(d), no significant decrease in EHV-1 infection of untreated CD172a
+ cells was observed between NA-treated and untreated virus. Taken together, these results indicated that EHV-1 depended on terminal sialic acid residues present on the cell surface for the initiation of its infection.
EHV-1 entry into CD172a
1 cells depends on cholesterol-rich lipid rafts, but does not occur via clathrin-or caveolae-mediated endocytosis
We characterized the endocytic route of EHV-1 entry into CD172a + cells using pharmacological/chemical inhibitors and co-localization assays. Pre-treatment of CD172a + cells with chlorpromazine and amantadine, two specific inhibitors of clathrin-mediated endocytosis, did not result in a significant decrease of EHV-1 infection compared with non-treated cells (control) and was independent of the EHV-1 strain used (Fig. 5a ). To control the effectiveness of these inhibitors, CD172a
+ cells untreated or pretreated with chlorpromazine or amantadine were analysed for transferrin uptake, a marker for clathrin-dependent endocytosis. Chlorpromazine and amantadine caused a significant reduction in the uptake of transferrin in CD172a + cells compared with untreated cells (Pv0.01) (Fig. 5d) . Moreover, no clear signal of co-localization between clathrin molecules and EHV-1 particles was detected in CD172a + cells at 0, 15 and 60 min post-inoculation (Fig. 5e ).
The lipid raft/caveolae-mediated pathway is characterized by the formation of primary endocytic vesicles dependent on cholesterol, lipid rafts, cellular tyrosine kinase and/or phosphatase activities (Pelkmans, 2005) . To disrupt lipid rafts and determine their role in EHV-1 entry into CD172a + cells, cells were pre-treated with filipin, a sterol-binding drug that sequesters cholesterol within the membrane, or with methyl-b-cyclodextrin (mbCD), which removes cholesterol from the plasma membrane. As shown in Fig (Fig. 5c ). However, no clear signal of co-colocalization between caveolin-1 molecules and EHV-1 particles was detected in CD172a + cells at 0, 15 and 60 min post-inoculation (Fig. 5f ). (untreated or pre-treated with 1 mg chlorpromazine ml 21 or 500 mM amantadine) were incubated with Alexa Fluor 647-labelled transferrin (100 mg ml
21
) for 1 h at 37 8C in the presence of the relevant inhibitor or medium. After 1 h, cells were washed and the uptake of transferrin (%) was analysed by flow cytometry. NS, Not significant; *P,0.05; **P,0.01; ***P,0.001; ****P,0.0001. (e, f) Visualization of EHV-1 03P37 particles (green) and clathrin protein (red) (e) or caveolin-1 protein (red) (f) in CD172a + cells. Nuclei were counterstained with Hoechst (blue). All confocal images represent a single section through a cell. Bar, 10 mm.
EHV-1 entry into CD172a
+ monocytic cells
Taken together, we concluded that the entry route of EHV-1 into CD172a + cells was not via a clathrin-or caveolaedependent mechanism. Moreover, these results suggested that cholesterol-rich lipid raft domains at the plasma membrane and cellular tyrosine kinase activity contributed to EHV-1 infection of CD172a + cells.
EHV-1 infection of CD172a 1 cells requires actin and dynamin, but does not occur via macropinocytosis Previous studies showed a possible role for macropinocytosis in HSV-1 infection (Nicola et al., 2003 (Nicola et al., , 2005 . To test whether macropinocytosis is involved in EHV-1 infection of CD172a
+ cells, cells were pre-treated with amiloride, a specific inhibitor of macropinocytosis, and latrunculin B, an inhibitor of actin polymerization. As shown in Fig. 6(a) , EHV-1 infection was not reduced in CD172a
+ cells treated with amiloride. In contrast, EHV-1 infection was significantly reduced by 55-65 % in cells treated with latrunculin B (Pv0.0001). To control the effectiveness of amiloride, CD172a
+ cells untreated or pre-treated with amiloride were analysed for dextran uptake, a marker for macropinocytosis. Pre-treatment of CD172a
+ cells with amiloride caused a significant reduction in the uptake of dextran compared with untreated cells (Pv0.0001) (Fig. 6b) .
The GTPase dynamin is a key component of clathrin-and caveolae-mediated endocytosis and phagocytosis (Gold et al., 1999; Mettlen et al., 2009; Nabi & Le, 2003) . Interestingly, the inhibition of uptake by dynamin constitutes a major difference between phagocytosis and macropinocytosis (Pelkmans & Helenius, 2003) . To test whether EHV-1 infection of CD172a + cells requires dynamin activity, cells were pre-treated with dynasore, a specific inhibitor of dynamin-1 and dynamin-2, which blocks dynamin-dependent endocytosis (Macia et al., 2006) . We found that EHV-1 (03P37 or 97P70) infection was significantly reduced in CD172a + cells treated with dynasore compared with untreated cells (Pv0.0001) (Fig. 6c) . Taken together, we concluded that EHV-1 infection was dependent on actin and dynamin, but did not occur via macro-pinocytosis.
Entry of EHV-1 into CD172a
1 cells requires a low-pH step To determine whether a pH drop was a crucial step in the infectious entry of EHV-1 into CD172a
+ cells, we examined the effects of the acidotropic agents ammonium chloride, chloroquine and monensin on EHV-1 infection. Pre-treatment of CD172a
+ cells with increased concentrations of these inhibitors resulted in a dose-dependent significant decrease of EHV-1 infection compared with non-treated cells (Pv0.01) and was independent of the EHV-1 strain used (Fig. 7) . EHV-1 infection was reduced by 90 % in CD172a + cells treated with 30 mM ammonium chloride or 50 mM chloroquine and was completely blocked in cells treated with 50 mM monensin. No significant difference in the efficiency of inhibition of EHV-1 infection was observed in CD172a + cells treated with inhibitors before inoculation, at the time of virus inoculation or 1 h post-inoculation, indicating that these agents did not affect binding of EHV-1 to cells, but rather blocked EHV-1 infection at a post-binding step (data not shown). treated with 100 mM amiloride) were incubated with FITC-dextran (1 mg ml 21 ) for 1 h at 37 8C in the presence of the inhibitor or medium. After 1 h, cells were washed and the uptake of dextran (%) was analysed by flow cytometry. Three independent experiments were performed and data represent mean¡SD. NS, Not significant; ****P,0.0001.
Taken together, these results showed that EHV-1 entered CD172a + cells in a low-pH-dependent manner.
DISCUSSION
In this study, we observed that EHV-1 only bound to a limited number of CD172a + cells (15-20 % compared with 70 % of RK-13 cells at 1 h post-inoculation). These results suggest that EHV-1 binds to specific receptors on the cell surface of a small population of CD172a + cells. Recently, we demonstrated that EHV-1 replication was highly restricted in CD172a + cells in vitro (Laval et al., 2015a) . We can now confirm that a block at the virus-binding level is partially responsible for the restricted viral replication in CD172a + cells.
To date, equine MHC-I molecules have been identified as a unique gD receptor for EHV-1 entry into equine cells, including endothelial cells of the central nervous system (Kurtz et al., 2010; Sasaki et al., 2011) . As MHC-I molecules are expressed on the cell surface of all nucleated cells, MHC-I cannot explain the restricted EHV-1 attachment and entry into a relatively small subset of CD172a + cells. In line with this, it was shown that MHC-I antibodies did not efficiently block EHV-1 entry into PBMCs, suggesting the presence of a different receptor(s) (Azab & Osterrieder, 2012 EHV-1 entry into CD172a + monocytic cells our understanding now that a V b 3 integrin is not used as the cellular receptor, crucial for the binding, but rather as a co-receptor for EHV-1 entry into CD172a + cells. Although speculative at this point, the interaction of EHV-1 with a V b 3 integrin may induce conformational changes of the cellular receptor and initiate signalling cascades that trigger uptake of EHV-1 within the cell. EHV-1 may use a V b 3 integrin to route its entry via endocytosis into CD172a
+ cells in order to shorten its exposure at the cell surface. Thus, we believe that the restricted expression of a V b 3 integrins on CD172a
+ cells may be an important determinant of EHV-1 tropism. Taken together, we suggest that co-receptor tropism on CD172a + cells might have direct implications in the pathogenesis on EHV-1, as is the case, for example, in HIV-1 infections (Goodenow & Collman, 2006) .
In this study, we could rule out that heparan sulphate is involved in EHV-1 infection of CD172a + cells. The lack of involvement of heparan sulphate in herpesvirus entry is rather exceptional. However, a recent study from Garrigues et al. (2014) showed that binding of the gammaherpesvirus Kaposi's sarcoma-associated herpesvirus is not dependent on heparan sulphate and that receptors other than heparan sulphate can mediate attachment to cells. To further examine the nature of the main receptor involved in the binding of EHV-1 to CD172a
+ cells, we focused our research on the role of sialic acids in EHV-1 infection of CD172a + cells. To date, several viruses, e.g. influenza virus or polyomaviruses, have been shown to bind specifically to sialic acid present on the surface of target cells, whilst its possible role in EHV-1 infection has not yet been described (Matrosovich et al., 2015) . We found that removal of sialic acid residues from cells inhibited EHV-1 infection of CD172a + cells by 90-100 %. In contrast, NA treatment of EHV-1 had no effect on infection of untreated CD172a + cells. These results suggest that EHV-1 may interact with a sialic acid-containing cell surface receptor on CD172a + cells. So far, influenza virus is the best-studied example of sialic acid involvement in viral entry. Influenza virus uses HA as an attachment receptor to bind to sialic acids on the cell surface (Wu & Air, 2004) . The type of linkage between terminal sialic acid and the second sugar is one of the major determinants of influenza virus tropism and host specificity (Connor et al., 1994; Matrosovich et al., 2000) . Further work will determine which sialylated glycans are present on CD172a + cells, and which are involved in EHV-1 binding and entry. The identity of EHV-1 envelope glycoprotein(s) involved as viral glycan-binding proteins should also be further investigated. Recent work from Andoh et al. (2015) demonstrated that EHV-1 gC protein had haemagglutination activity against equine red blood cells and that this activity was not inhibited by heparin. These results may suggest a potential role of EHV-1 gC as a viral lectin, involved in the binding of sialic acid residues on CD172a + cells.
Following binding to cell surface receptors, EHV-1 must be internalized to initiate infection. EHV-1 can enter target cells via direct fusion with the plasma membrane or via an endocytic/phagocytic entry pathway, which has been proposed to be the choice of entry of EHV-1 into PBMCs (Frampton et al., 2007; van de Walle et al., 2008) . Based on this published information, the last part of our study further defined the endocytic mechanism(s) of EHV-1 entry CD172a + cells using pharmacological inhibitors and co-localization assays. We demonstrated that EHV-1 enters CD172a
+ cells via an endocytic pathway that is independent of clathrin and caveolae, but is dependent on cholesterol, tyrosine kinase, actin and dynamin, and requires a low-pH step. In addition, we found that treatment of CD172a + cells with amiloride, a commonly used inhibitor of macropinocytosis, had no effect on EHV-1 infection. Hence, our data indicate that EHV-1 does not enter CD172a
+ cells by clathrin-or caveolaedependent endocytosis or macropinocytosis, and suggest that EHV-1 enters CD172a + cells via phagocytosis or via a non-classical endocytic pathway. Several indications point towards a phagocytic mechanism for EHV-1 in CD172a + cells. Phagocytosis is triggered by the recognition of large particles by cell surface phagocyte receptors, which leads to the polymerization of actin underneath the contact zone and the formation of a phagocytic 'cup' around the ingested particle (Mercer & Helenius, 2009) . This is usually a property of specialized cell types, including macrophages and dendritic cells. Phagocytosis (and EHV-1 entry in CD172a + cells) is sensitive to the depletion of cholesterol, implying the involvement of lipid rafts. However, it has been proposed that phagosomes are not formed entirely of lipid rafts, but rather contain both lipid raft and nonraft regions of the membrane, called mixed membrane domains (El-Sayed & Harashima, 2013; Kannan et al., 2008) . Phagocytosis (and EHV-1 entry in CD172a + cells) is also dependent on dynamin, a coordinating molecule that regulates the formation of membrane extensions around the particle (Di et al., 2003) . Finally, maturation of phagosomes is associated with a pH decrease (Flannagan et al., 2012) , in line with our observation that EHV-1 entry in CD172a
+ cells requires a pH drop. Phagocytosislike uptake of alphaherpesviruses was reported previously in a study by Clement et al. (2006) on HSV entry, which further supports the possibility that EHV-1 might enter CD172a + cells via phagocytosis. One argument against this entry route is the fact that EHV-1 virions are smaller (*200 nm) than the generally accepted size limit for phagocytosis (*500 nm). In any case, further studies are required to elucidate whether phagocytosis is the main mode of EHV-1 entry into CD172a + cells, a task hampered by a lack of specific pharmacological inhibitors. Surprisingly, we found that both neurovirulent and nonneurovirulent EHV-1 particles bound and entered CD172a + cells in a similar manner. These findings indicate that the mechanism of EHV-1 entry into CD172a + cells may not account for differences in the neuropathogenic versus abortigenic potential of EHV-1 in vivo, but may rather reflect differences in EHV-1 replication between the two strains. However, it is clear now that several block(s) exist in the replication cycle of EHV-1 in CD172a + cells, which may all be part of an immuneevasive strategy. Whilst a small fraction of CD172a + cells show EHV-1 particles bound to their surface, we think that not all viral particles will be internalized, and that not all viral genomes will be delivered to the nucleus and initiate efficient viral replication. Indeed, amongst 15-20 % of CD172a + cells with virus particles attached, we previously found that only 4-8 % of cells were susceptible to EHV-1 infection, dependent of the EHV-1 strain used (Laval et al., 2015a; Laval et al., in preparation) .
In conclusion, we showed that EHV-1 binds to a restricted number of CD172a + cells, indicating that EHV-1 may use specific receptor molecules. Based on our data, we propose that EHV-1 interacts with a sialic acid-containing cell surface receptor on CD172a
+ cells and that a V b 3 integrin acts as a co-receptor, which may explain the restricted tropism of the virus to particular CD172a + cells. In addition, our data suggest a phagocytosis-like uptake mechanism for EHV-1 in CD172a + cells. Further unravelling of this entry route of EHV-1 may provide new insights into the pathogenesis of EHV-1, both in vivo and in vitro, and may contribute to the development of new therapeutic strategies.
METHODS
Virus. Two Belgian EHV-1 strains were included in this study. The neurovirulent strain 03P37 was originally isolated in 2003 from the blood of a paralytic horse (Garré et al., 2009; van der Meulen et al., 2003a) and the non-neurovirulent strain 97P70 was first isolated in 1997 from the lungs of an aborted fetus (van der Meulen et al., 2000) .
Cells
Isolation of equine blood CD172a 1 cells. Blood CD172a + cells were isolated as described by Laval et al. (2015a, b) . Briefly, PBMCs were isolated by density centrifugation on Ficoll-Paque, resuspended in leukocyte medium (RPMI supplemented with 5 % FCS and antibiotics) and cultured for 12 h. Non-adhering lymphocytes were washed and the adherent cells consisted of w90 % of CD172a + cells, as assessed by flow cytometry.
Rabbit kidney epithelial (RK-13) cells RK-13 cells were used as a control cell line for blood CD172a
+ cells, and were maintained in minimal essential medium supplemented with antibiotics and 5 % FCS.
Cell viability
Cell viability was determined by flow cytometry prior to virus inoculation, using 1 mg propidium iodide ml 21 and was w90 % in all cell populations.
EHV-1 purification and Dio labelling. Viral purification was performed as described by Yang et al. (2014) . Briefly, culture fluids of EHV-1-infected (03P37 and 97P70) RK-13 cells were clarified and virus was collected after centrifugation. The virus suspension was run on a discontinuous OptiPrep gradient containing 10-30 % (w/v) iodixanol and centrifuged. The visible opalescent virus bands were harvested separately. The buffer was exchanged to HNE (5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4) buffer by the use of a 50 kDa filter device. Purified EHV-1 in solution was labelled with Dio dissolved in DMSO (Molecular Probes). Dio labelling did not significantly decrease virus infectivity. The purity of EHV-1 suspensions was evaluated by lipophilic labelling and immunofluorescence staining of EHV-1 gB as similarly described by Yang et al. (2014) . The staining was analysed using confocal microscopy by randomly selecting 10 regions. The ratio of EHV-1 gB-positive particles (virions) versus Dio-positive particles was calculated and referred to as the degree of viral purity (w90 %).
Kinetics of EHV-1 attachment. Cells were cooled to 4 uC, washed with ice-cold RPMI and inoculated at m.o.i. 1 or 10 with Dio-labelled EHV-1 (03P37 or 97P70) for 1 h on ice. Cells were washed twice with cold RPMI to remove unbound virus particles, and were further incubated on ice for 0, 5, 10, 15, 30 and 60 min. Cells were fixed with 1 % paraformaldehyde (PFA) for 10 min. Cell nuclei were stained with Hoechst 33342 (10 mg ml 21 ; Molecular Probes) for 10 min at 37 uC. Finally, coverslips were mounted on microscope slides and analysed by confocal microscopy.
The percentage of EHV-1-positive cells was calculated based on the number of cells with viral particles bound on the plasma membrane of 300 randomly selected cells. The mean number of virus particles attached per cell was calculated based on the number of particles attached at the plasma membrane of 10 randomly selected EHV-1-positive cells. For each cell, the entire plasma membrane was screened for the presence of virus particles by generating a z-stack.
Antibody-blocking assay. CD172a + cells were pre-incubated with neutralizing antibodies (10 or 50 mg ml 21 ) directed against CD29 (clone TDM29, IgG1; Merck Millipore), CD49d (clone 9F10, IgG2b; BD Pharmingen), CD11a/CD18 (clone CVS9, IgG1; AbD Serotec) or CD51/61 (clone 23C6, IgG1; BioLegend), or with isotype-matched control antibodies for 30 min at 37 uC. Cells were washed twice with RPMI and inoculated with EHV-1 (03P37 and 97P70, m.o.i. 1) for 1 h and further incubated for 12 h at 37 uC. Cells were fixed with methanol and incubated with a rabbit polyclonal antibody anti-IEP (1 : 1000) (kindly provided by Dr D. O'Callaghan, Louisiana State University, USA) to detect IEP expression, followed by a goat antirabbit IgG-FITC (1 : 100) antibody. The nuclei were counterstained with Hoechst and the percentage of IEP-positive cells was determined as previously described.
To determine the role of a V b 3 (CD51/61) integrin in EHV-1 binding to CD172a + cells, CD172a + cells were pre-incubated with CD51/61 at 10 mg ml 21 or with isotype-matched control antibodies for 30 min on ice. Cells were inoculated with Dio-labelled EHV-1 (03P37 or 97P70) particles (m.o.i. 1) for 1 h on ice. Cells were fixed with PFA 1 % and immunofluorescence staining was performed as described earlier.
Enzymic treatment. For enzymic removal of cell surface heparan sulphate or sialic acids, CD172a
+ cells were incubated with heparinase I and III blend (heparinase; 1 and 10 U ml 21 ) from Flavobacterium heparinum (Sigma) or NA (50 mU ml
21
) from Vibrio cholera (Roche Diagnostics) diluted in Dulbecco's PBS (DPBS) for 1 h at 37 uC. The concentration of heparinase and NA used in this study did not decrease the cell viability (w90 %). After washing, untreated and enzymic-treated cells were inoculated with EHV-1 03P37 or 97P70 strains at m.o.i. 1 for 1 h at 37 uC. Cells were washed and further incubated for 12 h at 37 uC.
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To remove sialic acids from the virus, EHV-1 03P37 and 97P70 suspensions were incubated on a shaker for 1 h at 37 uC with Glycocleave NA (V. cholera) enzyme beads (50 mU ml 21 ; GALAB Technologies) diluted in DPBS. Beads were washed two times with DPBS before incubation with the virus to remove buffers. Before inoculation, NA beads were separated from the virus by centrifugation (200 g, 10 min, 4 uC). Untreated virions were incubated in DPBS without beads and underwent the same manipulation as the NA-treated virus. Untreated cells were inoculated with either NAtreated or untreated virus at m.o.i. 1 for 1 h at 37 uC. Cells were washed and further incubated for 12 h. The percentage of IEP-positive cells was determined as described earlier.
Effect of different entry inhibitors on EHV-1 infection. Cells were pre-treated for 30 min at 37 uC with inhibitory compounds: 10 mM mbCD dissolved in PBS, 5 mg filipin III ml 21 dissolved in DMSO, 10 mg genistein ml 21 dissolved in DMSO, 500 mM amantadine dissolved in PBS, 1 mg chlorpromazine ml 21 dissolved in PBS, 100 mM amiloride dissolved in DMSO, 100 mM dynasore dissolved in DMSO and 20 mM latrunculin B dissolved in DMSO. Cells were then inoculated with EHV-1 03P37 or 97P70 strains (m.o.i. 1) in the presence of inhibitors and incubated for 1 h at 37 uC. After washing, cells were incubated for 12 h in the absence of inhibitors. Only mbCD and filipin were removed at the time of virus inoculation in order to avoid any effect on cholesterol in the viral envelope. The maximal concentration of inhibitors was optimized to ensure that viability of cells was always w85-90 %. The percentage of IEP-positive cells was determined as described earlier.
To assess the effectiveness of chlorpromazine, amantadine and amiloride on endocytosis inhibition, CD172a + cells (untreated or pretreated with 1 mg chlorpromazine ml 21 , 500 mM amantadine or 100 mM amiloride) were incubated with Alexa Fluor 647-labelled transferrin (100 mg ml 21 ) and FITC-labelled dextran (1 mg ml
21
) for 1 h at 37 uC in the presence of the relevant inhibitor or medium. Alexa Fluor 647-labelled transferrin and FITC-labelled dextran, used as positive controls for clathrin-mediated endocytosis and macropinocytosis, were obtained from Thermo Fischer and Sigma-Aldrich, respectively. After 1 h, cells were washed with PBS and the uptake of transferrin or dextran in CD172a + cells was analysed by flow cytometry. The internalization of fluorescent marker was calculated as the mean fluorescence intensity and expressed as a percentage of uptake. The 100 % uptake level was determined from CD172a + cells which had not been exposed to any inhibitor and had been incubated with the marker.
Colocalization with clathrin or caveolin-1. CD172a
+ cells were inoculated with Dio-labelled EHV-1 (03P37 or 97P70) (m.o.i. 1) for 0, 15 and 60 min at 37 uC, washed, and fixed with methanol. Cells were incubated with a rabbit polyclonal antibody anti-clathrin (1 : 200) (Biorbyt) or a goat polyclonal antibody anti-caveolin-1 (1 : 200) (Abcam), followed by a goat anti-rabbit IgG-Texas-Red (1 : 200) or rabbit anti-goat IgG-Texas-Red (1 : 200) antibodies. The nuclei were counterstained with Hoechst. As a negative control, mock-inoculated cells were stained following the aforementioned protocols.
Effect of acidotropic agents on EHV-1 infection. Cells were treated with several acidotropic agents: ammonium chloride, chloroquine, or monensin. Cells were pre-incubated with different concentrations of ammonium chloride (0, 10, 20 or 30 mM) dissolved in DMSO, chloroquine (0, 1, 10 or 50 mM) dissolved in PBS or monensin (0, 1, 10 or 50 mM) dissolved in DMSO for 2 h at 37 uC. Untreated and treated cells were inoculated with EHV-1 (m.o.i. 1) for 1 h in the presence of the drugs. After washing, cells were incubated in presence of the drugs for 12 h at 37 uC. The inhibitor concentrations used did not decrease the cell viability (w90 %). The percentage of IEP-positive cells was determined as described earlier.
Statistical analysis. Data were analysed with Prism 6 software (GraphPad). Data analysed for statistical significance were subjected to a two-way ANOVA. Prior to statistical analyses, all variables were checked for assumptions of ANOVA (equal variances and normal distribution of the standardized residuals) by Levene's test. When the variables were not equal, a Kruskal-Wallis test followed by pairwise comparisons was performed. Results with Pj0.05 were statistically significant.
